{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:44:31Z","timestamp":1788277471405,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The neuromuscular junction (NMJ) is essential for transmitting signals from motor neurons (MNs) to skeletal muscles (SKMs), and its dysfunction can lead to severe motor disorders. However, our understanding of the NMJ is limited by the absence of accurate human models. Although human induced pluripotent stem cell (iPSC)-derived models have advanced NMJ research, their application is constrained by challenges such as limited differentiation efficiency, lengthy generation times, and cryopreservation difficulties. To overcome these limitations, we developed a rapid human NMJ model using cryopreserved MNs and SKMs derived from iPSCs. Within 12 days of coculture, we successfully recreated NMJ-specific connectivity that closely mirrors in vivo synapse formation. Using this model, we investigated amyotrophic lateral sclerosis (ALS) and replicated ALS-specific NMJ cytopathies with SOD1 mutant and corrected isogenic iPSC lines. Quantitative analysis of 3D confocal microscopy images revealed a critical role of MNs in initiating ALS-related NMJ cytopathies, characterized by alterations in the volume, number, intensity, and distribution of acetylcholine receptors, ultimately leading to impaired muscle contractions. Our rapid and precise in vitro NMJ model offers significant potential for advancing research on NMJ physiology and pathology, as well as for developing treatments for NMJ-related diseases.<\/jats:p>","DOI":"10.1038\/s41420-025-02302-5","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T12:45:10Z","timestamp":1737809110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rapid iPSC-derived neuromuscular junction model uncovers motor neuron dominance in amyotrophic lateral sclerosis cytopathy"],"prefix":"10.1038","volume":"11","author":[{"given":"Hsiao-Chien","family":"Ting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Lin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinn-Zong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horng-Jyh","family":"Harn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-5944","authenticated-orcid":false,"given":"Chia-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"2302_CR1","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1002\/cphy.c210022","volume":"12","author":"LA Davis","year":"2022","unstructured":"Davis LA, Fogarty MJ, Brown A, Sieck GC. Structure and function of the mammalian neuromuscular junction. Compr Physiol. 2022;12:3731\u201366.","journal-title":"Compr Physiol"},{"key":"2302_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/joa.13463","volume":"241","author":"A Alhindi","year":"2022","unstructured":"Alhindi A, Boehm I, Chaytow H. Small junction, big problems: neuromuscular junction pathology in mouse models of amyotrophic lateral sclerosis (ALS). J Anat. 2022;241:1089\u2013107.","journal-title":"J Anat"},{"key":"2302_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnana.2016.00006","volume":"10","author":"M Boido","year":"2016","unstructured":"Boido M, Vercelli A. Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy. Front Neuroanat. 2016;10:6.","journal-title":"Front Neuroanat"},{"key":"2302_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrn3430","volume":"14","author":"W Robberecht","year":"2013","unstructured":"Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14:248\u201364.","journal-title":"Nat Rev Neurosci"},{"key":"2302_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s13311-016-0508-5","volume":"14","author":"R Smith","year":"2017","unstructured":"Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. 2017;14:762\u201372.","journal-title":"Neurotherapeutics"},{"key":"2302_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/14656566.2017.1319937","volume":"18","author":"H Sawada","year":"2017","unstructured":"Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother. 2017;18:735\u20138.","journal-title":"Expert Opin Pharmacother"},{"key":"2302_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/med.21528","volume":"39","author":"MK Jaiswal","year":"2019","unstructured":"Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39:733\u201348.","journal-title":"Med Res Rev"},{"key":"2302_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023;22:185\u2013212.","journal-title":"Nat Rev Drug Discov"},{"key":"2302_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnagi.2017.00068","volume":"9","author":"D Petrov","year":"2017","unstructured":"Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.","journal-title":"Front Aging Neurosci"},{"key":"2302_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fnmol.2016.00160","volume":"9","author":"ML Campanari","year":"2016","unstructured":"Campanari ML, Garcia-Ayllon MS, Ciura S, Saez-Valero J, Kabashi E. Neuromuscular junction impairment in amyotrophic lateral sclerosis: reassessing the role of acetylcholinesterase. Front Mol Neurosci. 2016;9:160.","journal-title":"Front Mol Neurosci"},{"key":"2302_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/mus.880170708","volume":"17","author":"JM Killian","year":"1994","unstructured":"Killian JM, Wilfong AA, Burnett L, Appel SH, Boland D. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve. 1994;17:747\u201354.","journal-title":"Muscle Nerve"},{"key":"2302_CR12","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1523\/JNEUROSCI.20-07-02534.2000","volume":"20","author":"D Frey","year":"2000","unstructured":"Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci. 2000;20:2534\u201342.","journal-title":"J Neurosci"},{"key":"2302_CR13","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.celrep.2017.11.008","volume":"21","author":"RA Jones","year":"2017","unstructured":"Jones RA, Harrison C, Eaton SL, Llavero Hurtado M, Graham LC, Alkhammash L, et al. Cellular and molecular anatomy of the human neuromuscular junction. Cell Rep. 2017;21:2348\u201356.","journal-title":"Cell Rep"},{"key":"2302_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/joa.13260","volume":"237","author":"I Boehm","year":"2020","unstructured":"Boehm I, Alhindi A, Leite AS, Logie C, Gibbs A, Murray O, et al. Comparative anatomy of the mammalian neuromuscular junction. J Anat. 2020;237:827\u201336.","journal-title":"J Anat"},{"key":"2302_CR15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/joa.13749","volume":"241","author":"SD Cahalan","year":"2022","unstructured":"Cahalan SD, Boehm I, Jones RA, Piercy RJ. Recognising the potential of large animals for modelling neuromuscular junction physiology and disease. J Anat. 2022;241:1120\u201332.","journal-title":"J Anat"},{"key":"2302_CR16","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1177\/0963689718775406","volume":"27","author":"CY Chang","year":"2018","unstructured":"Chang CY, Ting HC, Liu CA, Su HL, Chiou TW, Harn HJ, et al. Induced pluripotent stem cells: a powerful neurodegenerative disease modeling tool for mechanism study and drug discovery. Cell Transplant. 2018;27:1588\u2013602.","journal-title":"Cell Transplant"},{"key":"2302_CR17","doi-asserted-by":"crossref","unstructured":"Stoklund Dittlau K, Krasnow EN, Fumagalli L, Vandoorne T, Baatsen P, Kerstens A, et al. Generation of human motor units with functional neuromuscular junctions in microfluidic devices. J Vis Exp. 2021;175:e62959.","DOI":"10.3791\/62959"},{"key":"2302_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41596-019-0248-1","volume":"15","author":"T Osaki","year":"2020","unstructured":"Osaki T, Uzel SGM, Kamm RD. On-chip 3D neuromuscular model for drug screening and precision medicine in neuromuscular disease. Nat Protoc. 2020;15:421\u201349.","journal-title":"Nat Protoc"},{"key":"2302_CR19","doi-asserted-by":"crossref","unstructured":"Guo X, Smith V, Jackson M, Tran M, Thomas M, Patel A, et al. A human-based functional NMJ system for personalized ALS modeling and drug testing. Adv Ther. 2020;3:2000133.","DOI":"10.1002\/adtp.202000133"},{"key":"2302_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.745897","volume":"9","author":"VM Smith","year":"2021","unstructured":"Smith VM, Nguyen H, Rumsey JW, Long CJ, Shuler ML, Hickman JJ. A functional human-on-a-chip autoimmune disease model of myasthenia gravis for development of therapeutics. Front Cell Dev Biol. 2021;9:745897.","journal-title":"Front Cell Dev Biol"},{"key":"2302_CR21","doi-asserted-by":"crossref","unstructured":"Guo X, Badu-Mensah A, Thomas MC, McAleer CW, Hickman JJ. Characterization of functional human skeletal myotubes and neuromuscular junction derived-from the same induced pluripotent stem cell source. Bioengineering. 2020;7:133.","DOI":"10.3390\/bioengineering7040133"},{"key":"2302_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121752","volume":"289","author":"A Badu-Mensah","year":"2022","unstructured":"Badu-Mensah A, Guo X, Nimbalkar S, Cai Y, Hickman JJ. ALS mutations in both human skeletal muscle and motoneurons differentially affects neuromuscular junction integrity and function. Biomaterials. 2022;289:121752.","journal-title":"Biomaterials"},{"key":"2302_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121033","volume":"276","author":"OF Vila","year":"2021","unstructured":"Vila OF, Chavez M, Ma SP, Yeager K, Zholudeva LV, Colon-Mercado JM, et al. Bioengineered optogenetic model of human neuromuscular junction. Biomaterials. 2021;276:121033.","journal-title":"Biomaterials"},{"key":"2302_CR24","doi-asserted-by":"crossref","unstructured":"Chen D, Philippidou P, Brenha BF, Schaffer AE, Miranda HC. Scalable, optically-responsive human neuromuscular junction model reveals convergent mechanisms of synaptic dysfunction in familial ALS. bioRxiv. 2024;12:2024.01.11.575304.","DOI":"10.7554\/eLife.95388.1"},{"key":"2302_CR25","doi-asserted-by":"crossref","unstructured":"Lin CY, Yoshida M, Li LT, Ikenaka A, Oshima S, Nakagawa K, et al. iPSC-derived functional human neuromuscular junctions model the pathophysiology of neuromuscular diseases. JCI Insight. 2019;4:e124299.","DOI":"10.1172\/jci.insight.124299"},{"key":"2302_CR26","doi-asserted-by":"crossref","unstructured":"Lin CY, Yoshida M, Li LT, Saito MK. In vitro neuromuscular junction induced from human induced pluripotent stem cells. J Vis Exp. 2020;166:e61396.","DOI":"10.3791\/61396"},{"key":"2302_CR27","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41593-019-0498-9","volume":"22","author":"G Picchiarelli","year":"2019","unstructured":"Picchiarelli G, Demestre M, Zuko A, Been M, Higelin J, Dieterle S, et al. FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis. Nat Neurosci. 2019;22:1793\u2013805.","journal-title":"Nat Neurosci"},{"key":"2302_CR28","doi-asserted-by":"crossref","unstructured":"Costamagna D, Casters V, Beltra M, Sampaolesi M, Van Campenhout A, Ortibus E, et al. Autologous iPSC-derived human neuromuscular junction to model the pathophysiology of hereditary spastic paraplegia. Cells. 2022;11:3351.","DOI":"10.3390\/cells11213351"},{"key":"2302_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24776-4","volume":"12","author":"JD Pereira","year":"2021","unstructured":"Pereira JD, DuBreuil DM, Devlin AC, Held A, Sapir Y, Berezovski E, et al. Human sensorimotor organoids derived from healthy and amyotrophic lateral sclerosis stem cells form neuromuscular junctions. Nat Commun. 2021;12:4744.","journal-title":"Nat Commun"},{"key":"2302_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43781-3","volume":"14","author":"A Urzi","year":"2023","unstructured":"Urzi A, Lahmann I, Nguyen LVN, Rost BR, Garcia-Perez A, Lelievre N, et al. Efficient generation of a self-organizing neuromuscular junction model from human pluripotent stem cells. Nat Commun. 2023;14:8043.","journal-title":"Nat Commun"},{"key":"2302_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.stem.2019.12.007","volume":"26","author":"JM Faustino Martins","year":"2020","unstructured":"Faustino Martins JM, Fischer C, Urzi A, Vidal R, Kunz S, Ruffault PL, et al. Self-organizing 3D human trunk neuromuscular organoids. Cell Stem Cell. 2020;26:172\u201386.e6.","journal-title":"Cell Stem Cell"},{"key":"2302_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat5847","volume":"4","author":"T Osaki","year":"2018","unstructured":"Osaki T, Uzel SGM, Kamm RD. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci Adv. 2018;4:eaat5847.","journal-title":"Sci Adv"},{"key":"2302_CR33","doi-asserted-by":"crossref","unstructured":"Ting HC, Su HL, Chen MF, Harn HJ, Lin SZ, Chiou TW, et al. Robust generation of ready-to-use cryopreserved motor neurons from human pluripotent stem cells for disease modeling. Int J Mol Sci. 2022;23:13462.","DOI":"10.3390\/ijms232113462"},{"key":"2302_CR34","doi-asserted-by":"crossref","unstructured":"Ting HC, Yang HI, Harn HJ, Chiu IM, Su HL, Li X, et al. Coactivation of GSK3beta and IGF-1 attenuates amyotrophic lateral sclerosis nerve fiber cytopathies in SOD1 mutant patient-derived motor neurons. Cells. 2021;10:2773.","DOI":"10.3390\/cells10102773"},{"key":"2302_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.stem.2014.02.004","volume":"14","author":"H Chen","year":"2014","unstructured":"Chen H, Qian K, Du Z, Cao J, Petersen A, Liu H, et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014;14:796\u2013809.","journal-title":"Cell Stem Cell"},{"key":"2302_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7626","volume":"6","author":"ZW Du","year":"2015","unstructured":"Du ZW, Chen H, Liu H, Lu J, Qian K, Huang CL, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun. 2015;6:6626.","journal-title":"Nat Commun"},{"key":"2302_CR37","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.celrep.2017.01.040","volume":"18","author":"H Xi","year":"2017","unstructured":"Xi H, Fujiwara W, Gonzalez K, Jan M, Liebscher S, Van Handel B, et al. In vivo human somitogenesis guides somite development from hPSCs. Cell Rep. 2017;18:1573\u201385.","journal-title":"Cell Rep"},{"key":"2302_CR38","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1093\/brain\/awt164","volume":"136","author":"G Bruneteau","year":"2013","unstructured":"Bruneteau G, Simonet T, Bauche S, Mandjee N, Malfatti E, Girard E, et al. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain. 2013;136:2359\u201368.","journal-title":"Brain"},{"key":"2302_CR39","doi-asserted-by":"crossref","unstructured":"Limanaqi F, Busceti CL, Biagioni F, Cantini F, Lenzi P, Fornai F. Cell-clearing systems bridging repeat expansion proteotoxicity and neuromuscular junction alterations in ALS and SBMA. Int J Mol Sci. 2020;21:4021.","DOI":"10.3390\/ijms21114021"},{"key":"2302_CR40","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.celrep.2014.07.061","volume":"8","author":"S Carnio","year":"2014","unstructured":"Carnio S, LoVerso F, Baraibar MA, Longa E, Khan MM, Maffei M, et al. Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. Cell Rep. 2014;8:1509\u201321.","journal-title":"Cell Rep"},{"key":"2302_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70510-3","volume":"10","author":"A Badu-Mensah","year":"2020","unstructured":"Badu-Mensah A, Guo X, McAleer CW, Rumsey JW, Hickman JJ. Functional skeletal muscle model derived from SOD1-mutant ALS patient iPSCs recapitulates hallmarks of disease progression. Sci Rep. 2020;10:14302.","journal-title":"Sci Rep"},{"key":"2302_CR42","doi-asserted-by":"crossref","unstructured":"Cappello V, Francolini M. Neuromuscular junction dismantling in amyotrophic lateral sclerosis. Int J Mol Sci. 2017;18:2092.","DOI":"10.3390\/ijms18102092"},{"key":"2302_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/379657","volume":"2012","author":"D Krakora","year":"2012","unstructured":"Krakora D, Macrander C, Suzuki M. Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis. Neurol Res Int. 2012;2012:379657.","journal-title":"Neurol Res Int"},{"key":"2302_CR44","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.embor.7400826","volume":"7","author":"N Jokic","year":"2006","unstructured":"Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, Ruegg MA, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep. 2006;7:1162\u20137.","journal-title":"EMBO Rep"},{"key":"2302_CR45","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1111\/j.1749-6632.2010.05566.x","volume":"1198","author":"B Zorner","year":"2010","unstructured":"Zorner B, Schwab ME. Anti-Nogo on the go: from animal models to a clinical trial. Ann NY Acad Sci. 2010;1198:E22\u201334.","journal-title":"Ann NY Acad Sci"},{"key":"2302_CR46","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","volume":"71","author":"EJ Sorenson","year":"2008","unstructured":"Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770\u20135.","journal-title":"Neurology"},{"key":"2302_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/17482960802160370","volume":"10","author":"SA Sakowski","year":"2009","unstructured":"Sakowski SA, Schuyler AD, Feldman EL. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:63\u201373.","journal-title":"Amyotroph Lateral Scler"},{"key":"2302_CR48","doi-asserted-by":"crossref","unstructured":"Tarantino N, Canfora I, Camerino GM, Pierno S. Therapeutic targets in amyotrophic lateral sclerosis: focus on ion channels and skeletal muscle. Cells. 2022;11:415.","DOI":"10.3390\/cells11030415"},{"key":"2302_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/564612","volume":"2012","author":"CC Macarthur","year":"2012","unstructured":"Macarthur CC, Fontes A, Ravinder N, Kuninger D, Kaur J, Bailey M, et al. Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions. Stem Cells Int. 2012;2012:564612.","journal-title":"Stem Cells Int"},{"key":"2302_CR50","doi-asserted-by":"publisher","first-page":"963689723119817","DOI":"10.1177\/09636897231198172","volume":"32","author":"CY Lin","year":"2023","unstructured":"Lin CY, Ching YY, Wu SF, Lee YK, Fan HC, Su LY, et al. Coating-free culture medium for establishing and maintaining human induced pluripotent stem cells. Cell Transplant. 2023;32:9636897231198172.","journal-title":"Cell Transplant"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02302-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02302-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02302-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T12:45:19Z","timestamp":1737809119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02302-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2302"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02302-5","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}